Vaccination with sipuleucel-T produced IgG antibodies to secondary prostatic carcinoma antigens and prolonged survival in some patients, and assaying for antibodies may provide prognostic information and identify new vaccine targets. Additional approaches to improve T-cell responses are needed to improve the clinical efficacy. See related article by GuhaThakurta et al., p. 3619.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537829 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-15-0531 | DOI Listing |
Publication Analysis
Top Keywords
immune mechanisms
4
mechanisms major
4
major players
4
players cancer
4
cancer vaccination
4
vaccination sipuleucel-t
4
sipuleucel-t produced
4
produced igg
4
igg antibodies
4
antibodies secondary
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!